Press Releases

RubrYc Therapeutics, Inc., a company that conducts preclinical biotherapeutic research into epitope-selective therapies, announced a collaborative research collaboration and licensing agreement with Zai Labs, Inc. in the use of the MEMs (Meso-scale Engineered Molecules) platform, used to identify monoclonal antibodies with enhanced biological function for an undisclosed oncological target. Under the terms of the agreement, RubrYc and Zai Labs will work together to single out product

ATMPS Ltd, a leader in blockchain-based “vein to vein” cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, today announce a global collaboration to create seamless integration between their respective data platforms to support the development of Advanced Therapies. The non-exclusive partnership will result in the integration of Ori’s proprietary CGT manufacturing platform’s

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD A

SciNeuro Pharmaceuticals, an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synucl

BridgeBio Pharma, Inc.announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers. “We are honored to begin collaborating with Roswell Park, which is renowned for its excellence in cancer research and its mission to set the gold standard for treating patients with genetically driven cancers,” said BridgeBio CEO and founder Neil Kumar, Ph.D. Under

Actimed Therapeutics Ltd., a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, announced a license agreement for S-oxprenolol to Faraday Pharmaceuticals, Inc., a biopharmaceutical company focused on improving outcomes of critical illnesses by reducing the loss of cardiac and skeletal muscle function. S-oxprenolol is one of a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. Usin

C4 Therapeutics, Inc., a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, presented preclinical data for CFT7455, the Company’s lead program, a MonoDACTM degrader targeting IKZF1/3 for the treatment of hematologic malignancies. These results, which support clinical evaluation of CFT7455 in multiple myeloma, were delivered as a late-breaking oral presentation during the first session of the

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-201 in adult patients with moderate-to-severe Atopic Dermatitis (AD). The global, randomized, double-blind, placebo-controlled, dose-ranging clinica

Biogen Inc.and Bio-Thera Solutions, Ltd. announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 (IL-6) receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA®1 (tocilizumab). ACTEMRA®’s primary indication is for moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis, systemic juvenile idiopath

Rigel Pharmaceuticals, Inc. announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and infl